BeOne Medicines (ONC) Payables (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Payables of $423.5 million for Q1 2026, up 16.2% year-over-year from $364.5 million in Q1 2025, and down 11.58% quarter-over-quarter from $479.0 million in Q4 2025.
BeOne Medicines (ONC) Payables (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Payables for 12 consecutive years, with $423.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 16.2% year-over-year to $423.5 million; the TTM figure through Mar 2026 stood at $423.5 million (up 16.2% YoY), while the FY2025 annual figure was $479.0 million, down 61.88% from the prior year.
- Payables retreated to $423.5 million in Q1 2026 per ONC's latest filing, from $479.0 million in the prior quarter.
- Across five years, Payables topped out at $1.3 billion in Q4 2024 and bottomed at $234.4 million in Q2 2022.
- Historically, Payables has averaged $427.2 million across 5 years, with a median of $333.0 million in 2024.
- Annual changes were most pronounced in 2024 — Payables soared 298.76% — and 2025, when it tumbled 61.88%.
- BeOne Medicines' Payables stood at $294.8 million in 2022, then climbed by 6.9% to $315.1 million in 2023, then jumped by 298.76% to $1.3 billion in 2024, then sank by 61.88% to $479.0 million in 2025, then decreased by 11.58% to $423.5 million in 2026.
- Business Quant data shows ONC's Payables at $423.5 million in Q1 2026, $479.0 million in Q4 2025, and $1.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 25.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 470.30 Mn |
| Mar 31, 2026 | 423.55 Mn |
| Dec 31, 2025 | 479.04 Mn |
| Sep 30, 2025 | 1.20 Bn |
| Jun 30, 2025 | 360.78 Mn |
| Mar 31, 2025 | 364.50 Mn |
| Dec 31, 2024 | 1.26 Bn |
| Sep 30, 2024 | 307.53 Mn |
| Jun 30, 2024 | 333.02 Mn |
| Mar 31, 2024 | 356.58 Mn |
| Dec 31, 2023 | 315.11 Mn |
| Sep 30, 2023 | 341.86 Mn |
| Jun 30, 2023 | 266.98 Mn |
| Mar 31, 2023 | 241.36 Mn |
| Dec 31, 2022 | 294.78 Mn |
| Sep 30, 2022 | 252.07 Mn |
| Jun 30, 2022 | 234.36 Mn |
| Mar 31, 2022 | 236.92 Mn |
| Dec 31, 2021 | 262.40 Mn |
| Sep 30, 2021 | 206.20 Mn |